---
layout: default
title: EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment
---

# EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment

**arXiv**: [2512.14019v1](https://arxiv.org/abs/2512.14019) | [PDF](https://arxiv.org/pdf/2512.14019.pdf)

**ä½œè€…**: Juseung Yun, Sunwoo Yu, Sumin Ha, Jonghyun Kim, Janghyeon Lee, Jongseong Jang, Soonyoung Lee

**åˆ†ç±»**: cs.LG, q-bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºEXAONE Path 2.5ç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œé€šè¿‡å¤šç»„å­¦å¯¹é½è§£å†³ç™Œç—‡å¤šæ¨¡æ€å»ºæ¨¡ä¸è¶³çš„é—®é¢˜**

**å…³é”®è¯**: `ç—…ç†å­¦åŸºç¡€æ¨¡åž‹` `å¤šæ¨¡æ€å¯¹é½` `å¤šç»„å­¦æ•´åˆ` `å¯¹æ¯”å­¦ä¹ ` `ç²¾å‡†è‚¿ç˜¤å­¦` `å…¨åˆ‡ç‰‡å›¾åƒåˆ†æž` `RNA-seqå»ºæ¨¡` `ç”Ÿç‰©ä¿¡æ¯å­¦`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šçŽ°æœ‰ç—…ç†å­¦æ¨¡åž‹ä¸»è¦ä¾èµ–å›¾åƒæ•°æ®ï¼Œéš¾ä»¥æ•æ‰ç™Œç—‡è¿›å±•ä¸­è·¨åˆ†å­å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œå¯¼è‡´å¯¹è‚¿ç˜¤ç”Ÿç‰©å­¦çš„ç†è§£ä¸å…¨é¢ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæå‡ºEXAONE Path 2.5ï¼Œé€šè¿‡å¤šæ¨¡æ€SigLIPæŸå¤±ã€F-RoPEæ¨¡å—å’Œé¢†åŸŸä¸“ç”¨åŸºç¡€æ¨¡åž‹ï¼Œå®žçŽ°ç»„ç»‡å­¦ä¸Žå¤šç»„å­¦æ•°æ®çš„è”åˆå»ºæ¨¡ã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šåœ¨Patho-BenchåŸºå‡†ä¸Šè¾¾åˆ°æœ€å…ˆè¿›æ€§èƒ½ï¼Œåœ¨å†…éƒ¨ä¸´åºŠæ•°æ®ä¸­è¡¨çŽ°å‡ºé«˜é€‚åº”æ€§ï¼ŒéªŒè¯äº†å¤šæ¨¡æ€è®¾è®¡çš„æœ‰æ•ˆæ€§ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç™Œç—‡è¿›å±•æºäºŽå¤šä¸ªç”Ÿç‰©å±‚é¢çš„ç›¸äº’ä½œç”¨ï¼Œç‰¹åˆ«æ˜¯è¶…è¶Šå½¢æ€å­¦ä¸”æ¶‰åŠåˆ†å­å±‚é¢çš„è¿‡ç¨‹ï¼Œè¿™äº›æ˜¯ä»…ä¾èµ–å›¾åƒçš„æ¨¡åž‹æ— æ³•æ•æ‰çš„ã€‚ä¸ºäº†æ›´å…¨é¢åœ°åˆ»ç”»è¿™ä¸€ç”Ÿç‰©å›¾æ™¯ï¼Œæˆ‘ä»¬æå‡ºäº†EXAONE Path 2.5ï¼Œä¸€ä¸ªç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œå®ƒè”åˆå»ºæ¨¡ç»„ç»‡å­¦ã€åŸºå› ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œè½¬å½•ç»„å­¦ç­‰å¤šæ¨¡æ€æ•°æ®ï¼Œç”Ÿæˆåæ˜ è‚¿ç˜¤ç”Ÿç‰©å­¦æ›´å…¨é¢çš„æ•´åˆæ‚£è€…è¡¨å¾ã€‚æˆ‘ä»¬çš„æ–¹æ³•åŒ…å«ä¸‰ä¸ªå…³é”®ç»„ä»¶ï¼š(1) å¤šæ¨¡æ€SigLIPæŸå¤±ï¼Œå®žçŽ°è·¨å¼‚è´¨æ¨¡æ€çš„å…¨é…å¯¹å¯¹æ¯”å­¦ä¹ ï¼›(2) ç‰‡æ®µæ„ŸçŸ¥æ—‹è½¬ä½ç½®ç¼–ç (F-RoPE)æ¨¡å—ï¼Œä¿ç•™å…¨åˆ‡ç‰‡å›¾åƒä¸­çš„ç©ºé—´ç»“æž„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ï¼›(3) é’ˆå¯¹å…¨åˆ‡ç‰‡å›¾åƒå’ŒRNA-seqçš„é¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡åž‹ï¼Œæä¾›åŸºäºŽç”Ÿç‰©å­¦çš„åµŒå…¥ï¼Œä»¥å®žçŽ°ç¨³å¥çš„å¤šæ¨¡æ€å¯¹é½ã€‚æˆ‘ä»¬åœ¨ä¸¤ä¸ªäº’è¡¥åŸºå‡†ä¸Šè¯„ä¼°EXAONE Path 2.5ï¼šä¸€ä¸ªå†…éƒ¨çœŸå®žä¸–ç•Œä¸´åºŠæ•°æ®é›†å’Œè¦†ç›–80ä¸ªä»»åŠ¡çš„Patho-BenchåŸºå‡†ã€‚æˆ‘ä»¬çš„æ¡†æž¶å±•ç¤ºäº†é«˜æ•°æ®å’Œå‚æ•°æ•ˆçŽ‡ï¼Œåœ¨Patho-Benchä¸Šè¾¾åˆ°ä¸Žæœ€å…ˆè¿›åŸºç¡€æ¨¡åž‹ç›¸å½“çš„æ€§èƒ½ï¼ŒåŒæ—¶åœ¨å†…éƒ¨ä¸´åºŠè®¾ç½®ä¸­è¡¨çŽ°å‡ºæœ€é«˜çš„é€‚åº”æ€§ã€‚è¿™äº›ç»“æžœçªæ˜¾äº†åŸºäºŽç”Ÿç‰©å­¦çš„å¤šæ¨¡æ€è®¾è®¡çš„ä»·å€¼ï¼Œå¹¶å¼ºè°ƒäº†æ•´åˆåŸºå› åž‹åˆ°è¡¨åž‹å»ºæ¨¡å¯¹ä¸‹ä¸€ä»£ç²¾å‡†è‚¿ç˜¤å­¦çš„æ½œåŠ›ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

EXAONE Path 2.5çš„æ•´ä½“æ¡†æž¶æ˜¯ä¸€ä¸ªç—…ç†å­¦åŸºç¡€æ¨¡åž‹ï¼Œæ—¨åœ¨æ•´åˆç»„ç»‡å­¦å›¾åƒä¸ŽåŸºå› ç»„ã€è¡¨è§‚é—ä¼ å’Œè½¬å½•ç»„ç­‰å¤šç»„å­¦æ•°æ®ã€‚å…³é”®æŠ€æœ¯åˆ›æ–°ç‚¹åŒ…æ‹¬ï¼šé‡‡ç”¨å¤šæ¨¡æ€SigLIPæŸå¤±è¿›è¡Œå…¨é…å¯¹å¯¹æ¯”å­¦ä¹ ï¼Œä»¥å¯¹é½å¼‚è´¨æ¨¡æ€ï¼›è®¾è®¡F-RoPEæ¨¡å—ï¼Œåœ¨å…¨åˆ‡ç‰‡å›¾åƒä¸­ä¿ç•™ç©ºé—´ç»“æž„å’Œç»„ç»‡ç‰‡æ®µæ‹“æ‰‘ï¼›å¹¶æž„å»ºé¢†åŸŸä¸“ç”¨å†…éƒ¨åŸºç¡€æ¨¡åž‹ï¼Œä¸ºå…¨åˆ‡ç‰‡å›¾åƒå’ŒRNA-seqæä¾›ç”Ÿç‰©å­¦åŸºç¡€çš„åµŒå…¥ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•çš„ä¸»è¦åŒºåˆ«åœ¨äºŽï¼Œå®ƒè¶…è¶Šäº†å•ä¸€å›¾åƒæ¨¡æ€ï¼Œé€šè¿‡å¤šç»„å­¦å¯¹é½å®žçŽ°æ›´å…¨é¢çš„è‚¿ç˜¤ç”Ÿç‰©å­¦è¡¨å¾ï¼Œæé«˜äº†æ¨¡åž‹çš„ç”Ÿç‰©è§£é‡Šæ€§å’Œé€‚åº”æ€§ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

åœ¨Patho-BenchåŸºå‡†çš„80ä¸ªä»»åŠ¡ä¸­ï¼ŒEXAONE Path 2.5è¾¾åˆ°ä¸Žæœ€å…ˆè¿›åŸºç¡€æ¨¡åž‹ç›¸å½“çš„æ€§èƒ½ï¼ŒåŒæ—¶åœ¨å†…éƒ¨çœŸå®žä¸–ç•Œä¸´åºŠæ•°æ®é›†ä¸­è¡¨çŽ°å‡ºæœ€é«˜çš„é€‚åº”æ€§ï¼ŒéªŒè¯äº†å…¶é«˜æ•°æ®å’Œå‚æ•°æ•ˆçŽ‡ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨ç²¾å‡†è‚¿ç˜¤å­¦é¢†åŸŸå…·æœ‰å¹¿æ³›åº”ç”¨æ½œåŠ›ï¼Œå¯ç”¨äºŽç™Œç—‡è¯Šæ–­ã€é¢„åŽé¢„æµ‹å’Œæ²»ç–—å“åº”è¯„ä¼°ï¼Œé€šè¿‡æ•´åˆå¤šæ¨¡æ€æ•°æ®æä¾›æ›´ä¸ªæ€§åŒ–çš„åŒ»ç–—å†³ç­–æ”¯æŒï¼ŒæŽ¨åŠ¨ä¸‹ä¸€ä»£ç²¾å‡†åŒ»ç–—çš„å‘å±•ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology foundation model that jointly models histologic, genomic, epigenetic and transcriptomic modalities, producing an integrated patient representation that reflects tumor biology more comprehensively. Our approach incorporates three key components: (1) multimodal SigLIP loss enabling all-pairwise contrastive learning across heterogeneous modalities, (2) a fragment-aware rotary positional encoding (F-RoPE) module that preserves spatial structure and tissue-fragment topology in WSI, and (3) domain-specialized internal foundation models for both WSI and RNA-seq to provide biologically grounded embeddings for robust multimodal alignment. We evaluate EXAONE Path 2.5 against six leading pathology foundation models across two complementary benchmarks: an internal real-world clinical dataset and the Patho-Bench benchmark covering 80 tasks. Our framework demonstrates high data and parameter efficiency, achieving on-par performance with state-of-the-art foundation models on Patho-Bench while exhibiting the highest adaptability in the internal clinical setting. These results highlight the value of biologically informed multimodal design and underscore the potential of integrated genotype-to-phenotype modeling for next-generation precision oncology.

